Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis.

IF 1.7 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

American journal of translational research Pub Date : 2024-07-15 eCollection Date: 2024-01-01 DOI:10.62347/RNLQ2888

Tao Wang, Jiwen Xu, Yiming Sun, Li Liu, Yue Li, Xiaojun Cai, Ming Chen, Yingying Fang

{"title":"Efficacy of sulodexide in treating idiopathic membranous nephropathy among Chinese patients: a meta-analysis.","authors":"Tao Wang, Jiwen Xu, Yiming Sun, Li Liu, Yue Li, Xiaojun Cai, Ming Chen, Yingying Fang","doi":"10.62347/RNLQ2888","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of Sulodexide in treating idiopathic membranous nephropathy (IMN) in the Chinese population.Methods: We systematically reviewed all eligible randomized clinical trials (RCTs) conducted in China that investigated the effects of Sulodexide on IMN. Three RCTs published between 2013 and 2022 were included, encompassing a total of 146 patients. The primary outcomes evaluated were changes in urine total protein (UTP), serum albumin (ALB), cholesterol (CHOL), and fibrinogen (FIB) levels.Results: Statistically significant differences were observed in the Sulodexide treatment group compared to the control group for the following parameters: reduction in UTP and CHOL, increase in ALB, and reduction in FIB levels.Conclusion: Sulodexide, when combined with conventional therapy, effectively reduces UTP and CHOL levels, decreases FIB levels, and increases ALB in Chinese patients with IMN.","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301453/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/RNLQ2888","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy of Sulodexide in treating idiopathic membranous nephropathy (IMN) in the Chinese population.

Methods: We systematically reviewed all eligible randomized clinical trials (RCTs) conducted in China that investigated the effects of Sulodexide on IMN. Three RCTs published between 2013 and 2022 were included, encompassing a total of 146 patients. The primary outcomes evaluated were changes in urine total protein (UTP), serum albumin (ALB), cholesterol (CHOL), and fibrinogen (FIB) levels.

Results: Statistically significant differences were observed in the Sulodexide treatment group compared to the control group for the following parameters: reduction in UTP and CHOL, increase in ALB, and reduction in FIB levels.

Conclusion: Sulodexide, when combined with conventional therapy, effectively reduces UTP and CHOL levels, decreases FIB levels, and increases ALB in Chinese patients with IMN.

查看原文本刊更多论文

舒洛地特治疗中国特发性膜性肾病的疗效：一项荟萃分析。

目的：评估舒洛地特治疗特发性膜性肾病（IMN）的疗效：评估舒洛地特治疗中国特发性膜性肾病（IMN）的疗效：我们系统回顾了在中国进行的所有符合条件的研究舒洛地特对特发性膜性肾病疗效的随机临床试验（RCT）。共纳入了 2013 年至 2022 年间发表的三项 RCT，共计 146 名患者。评估的主要结果是尿总蛋白（UTP）、血清白蛋白（ALB）、胆固醇（CHOL）和纤维蛋白原（FIB）水平的变化：结果：与对照组相比，舒洛地特治疗组在以下参数上有明显统计学差异：UTP 和 CHOL 下降、ALB 上升、FIB 水平下降：结论：舒洛地特与常规治疗相结合，可有效降低中国IMN患者的UTP和CHOL水平，降低FIB水平，增加ALB。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL

自引率

0.00%

发文量

552

期刊介绍： Information not localized